A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
R-Pharm
Seagen Inc.
Pfizer
Eli Lilly and Company
Pfizer
Bristol-Myers Squibb
National Cancer Institute (NCI)
Novartis
EMD Serono
Pfizer
AstraZeneca
City of Hope Medical Center
GlaxoSmithKline
City of Hope Medical Center
Enliven Therapeutics
University of Alabama at Birmingham
Toray Industries, Inc
City of Hope Medical Center
Jiangsu Hansoh Pharmaceutical Co., Ltd.
IGM Biosciences, Inc.
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Hansoh BioMedical R&D Company
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Ono Pharmaceutical Co., Ltd.
Canadian Cancer Trials Group
Barbara Ann Karmanos Cancer Institute
Ludwig Institute for Cancer Research
Sumitomo Pharma Co., Ltd.
GSO Global Clinical Research BV
Gilead Sciences
Eli Lilly and Company
TG Therapeutics, Inc.
M.D. Anderson Cancer Center
Haihe Biopharma Co., Ltd.
Mayo Clinic
UNC Lineberger Comprehensive Cancer Center
University of Miami
University of Chicago
M.D. Anderson Cancer Center
Jiangsu Simcere Pharmaceutical Co., Ltd.
UNC Lineberger Comprehensive Cancer Center
Eli Lilly and Company
National Cancer Institute (NCI)
Daiichi Sankyo
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)